Externalized Groshong Catheters and Hickman Ports for Central Venous Access in Gynecologic Oncology Patients

Gleeson, Noreen; Fiorica, James V.; Mark, James E.; Pinelli, Donna M.; Hoffman, Mary; Roberts, William S.; Cavanagh, Denis

doi:10.1006/gyno.1993.1306

Cited by 28 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanical complications have been reported to occur in approximately 20% of the externalized catheters [8][9][10][11] and 4% of subcutaneous devices [12]. Catheter-related infections are reported in 7 to 32% of patients with Groshong catheters [13][14][15] and in 11 to 45% of patients with Hickman catheters [16][17][18]. In a recent analysis of several published studies, symptomatic thrombosis has been reported with an incidence of 0.3 to 28.3% [19].…”

Section: Discussionmentioning

confidence: 95%

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Masci

Magagnoli

Pedicini

et al. 2006

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Masci

Magagnoli

Pedicini

et al. 2006

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…We administered 5-FU as true boluses with an approximate injection time of 3 min, which may be associated with more adverse events than short (about 15 min) infusions (Andre et al, 2001). We also included VAD-related adverse effects, though they were infrequent in comparison to some other series (Carde et al, 1989;Gleeson et al, 1993;Kock et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

et al. 2007

View full text Add to dashboard Cite

5-Fluorouracil (5-FU)-based chemotherapy is frequently associated with diarrhoea. We compared two 5-FU-based regimens and the effect of Lactobacillus and fibre supplementation on treatment tolerability. Patients diagnosed with colorectal cancer (n ¼ 150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy. On the basis of random allocation, the study participants did or did not receive Lactobacillus rhamnosus GG supplementation (1 -2 Â 10 10 per day) and fibre (11 g guar gum per day) during chemotherapy. Patients who received Lactobacillus had less grade 3 or 4 diarrhoea (22 vs 37%, P ¼ 0.027), reported less abdominal discomfort, needed less hospital care and had fewer chemotherapy dose reductions due to bowel toxicity. No Lactobacillus-related toxicity was detected. Guar gum supplementation had no influence on chemotherapy tolerability. The simplified de Gramont regimen was associated with fewer grade 3 or 4 adverse effects than the Mayo regimen (45 vs 89%), and with less diarrhoea. We conclude that Lactobacillus GG supplementation is well tolerated and may reduce the frequency of severe diarrhoea and abdominal discomfort related to 5-FU-based chemotherapy.

show abstract

“…Thus, the method of insertion may affect the outcome. A number of the studies attempted to compare CVAPD with either Groshong catheters or Hickman catheters and consistently found a higher rate of complications in the central external catheters (Mueller et al, 1992;Gleeson et al, 1993;Groeger et al, 1993;Eastridge and Lefor, 1995) (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature

et al. 2004

View full text Add to dashboard Cite

Central venous access port devices (CVAPD) are necessary for delivery of prolonged infusional chemotherapy or in patients with poor peripheral venous access. Previous studies of Hickman catheters report complication rates in about 45% of patients. Our aim was to assess the early and late complication rate, and duration that the CVAPD remained functional, following insertion by interventional radiologists in patients with solid tumours. A prospective study was undertaken in 110 consecutive patients who had insertion of 111 subclavian CVAPD. The median age of patients was 57 years (range 17 -83), 64 were females; 68 patients (61%) had gastrointestinal tumours and 25 (23%) had breast cancer. CVAPD were successfully implanted in all but one patient. There were four (4%) immediate major complications: thrombosis 2 and pneumothorax 2. Nine patients (8%) had bruising or pain. Four devices (4%) became infected. In total, 100 CVAPD (90%) were either removed as planned at the end of treatment (n ¼ 23) after a median 203 days, or remained in situ for a median of 237 days (7 -1133). Premature removal occurred in eight patients due to infection (n ¼ 4), thrombosis (n ¼ 3) or faulty device (n ¼ 1). Four patients were lost to follow-up. Radiological insertion of CVAPD is safe and convenient with low rates of complications.

show abstract

Externalized Groshong Catheters and Hickman Ports for Central Venous Access in Gynecologic Oncology Patients

Cited by 28 publications

References 0 publications

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature

Contact Info

Product

Resources

About